StockMarketWire.com - Oxford BioDynamics has entered into a development agreement with two of the top 10 global pharmaceutical companies, which are collaborating on an anti PD-L1 therapy.

Oxford BioDynamics would identify biomarkers in whole blood of non-small cell lung carcinoma (NSCLC) patients to assist in differentiating between responders and non-responders to an anti PD-L1 therapy, using its EpiSwitch biomarker platform.

It said the agreement had the potential to be extended in the form of a licensing agreement, which would see the development of an EpiSwitch-class blood-based test, based on the work undertaken as part of the current agreement, for use by the pharmaceutical companies.

Financial terms of the agreement are not disclosed.






Story provided by StockMarketWire.com